- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
ImageneBio, Inc.(IMA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IMA
11/13/2026: IMA (1-star) is currently NOT-A-BUY. Pass it for now.
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for immunological and inflammatory diseases. Its primary asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody designed to address conditions like atopic dermatitis with a differentiated safety profile. While the company benefits from an experienced leadership team and an optimized clinical pipeline following its 2025 merger, it remains pre-revenue and heavily dependent on external capital financing. Key risks include high clinical trial attrition, intense competition from major pharmaceutical developers, and equity dilution. The stock suits growth-oriented or speculative investors willing to weather high volatility ahead of upcoming clinical data catalysts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Offers high-beta clinical expansion potential balanced by early-stage pipeline risks. |
| Momentum investor | Strong fit while signal remains positive | Attracts short-term trading volume around clinical trial catalysts and biotech sector rallies. |
| Value investor | Weak fit | Lacks current earnings, traditional valuation metrics, or positive cash flows. |
| Dividend investor | Weak fit | Does not pay dividends as capital is entirely consumed by clinical research. |
| Low-risk investor | Weak fit | Exhibits high price volatility and clinical binary outcome risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Stock prices fluctuate sharply based on clinical data readouts and market sentiment. |
| Valuation risk | High | Valuations rely heavily on prospective future drug approvals rather than current fundamentals. |
| Competition risk (name the main competitor theme, e.g. AI competition) | Medium / high | Large pharmaceutical competitors possess superior resources in developing competing immunology therapies. |
| Business quality | Medium | The company features promising science but lacks a diversified commercial revenue base. |
| Dividend income | Low / none | No income is returned to shareholders via dividends. |
| Execution risk | High | Success depends entirely on the flawless execution and positive clinical outcomes of IMG-007. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.22M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 12.3K shares | Beta - | 52 Weeks Range 3.34 - 8.25 | Updated Date 11/15/2026 |
52 Weeks Range 3.34 - 8.25 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.11 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -38.89% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biopharmaceutical Licensing and Collaborations | Upfront payments, milestone fees, and potential royalties derived from codevelopment or licensing agreements. | The company is currently pre-revenue and depends on partnerships or capital raises rather than product sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -82.06M | Price to Sales(TTM) - |
Enterprise Value -82.06M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 31.86 | Enterprise Value to EBITDA - | Shares Outstanding 12.46M | Shares Floating 5.83M |
Shares Outstanding 12.46M | Shares Floating 5.83M | ||
Percent Insiders 16.19 | Percent Institutions 54.48 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

